"Zhongsheng Quanpeptide" Raises Over 300 Million Yuan in Series C Funding to Accelerate Global Expansion of Peptide-Based Innovative Drugs
It has secured multiple international partnerships with MNCs including Novartis and Eli Lilly and Company.
On May 11, 2026, Hunan Zhongsheng Quanpeptide Biotech Co., Ltd. (hereinafter referred to as "Zhongsheng Quanpeptide"), a leading domestic platform for peptide-based innovative drug discovery and development, announced that it has recently completed an oversubscribed Series C financing round of over RMB 300 million, with a post-money valuation of nearly RMB 5 billion. This round was co-led by Lilly Asia Ventures and CDH Investments, with participation from multiple existing and new investors, including Gaorong Ventures.
This marks another major milestone for Zhongsheng Quanpeptide following its Series B round in July 2025, signaling capital markets' strong endorsement of the company's technology platform, R&D capabilities, and commercialization prospects. The proceeds will primarily accelerate clinical advancement of core pipeline programs, upgrade and iterate its AI drug discovery platform, build out its international talent team, and expand its global partnership footprint.
Deep Roots in Peptide-Based Innovative Drugs
50+ Innovative Drug Programs in Pipeline
Since its founding, Zhongsheng Quanpeptide has remained focused on peptide-based new drug discovery and development. The company has built six complementary molecular discovery library platforms encompassing an ultra-large peptide information compression library (PICT library), phage display library, mRNA display library, animal peptide library, nanocyclic peptide library, and AI virtual library. It has also established twelve advantaged technology platforms spanning high-throughput screening, AI-driven drug R&D, peptide-drug conjugation, and BBB blood-brain barrier penetration.
The company has developed significant strengths in cutting-edge areas including peptide-radionuclide conjugates (PRC), peptide-drug conjugates (PDC), and peptide-oligonucleotide conjugates (POC). To date, it has laid out more than 50 innovative drug programs in its pipeline.
Major BD Deals with Multinational Pharma
Validating R&D Strength and Global Capabilities
In early 2026, the company successively reached global licensing and collaboration agreements with MNCs including Eli Lilly and Company and Novartis for peptide pipeline assets, securing nearly $70 million in upfront payments with additional milestone payments and sales royalties to follow. These deals fully validate the company's R&D capabilities and international partnership capacity in the global peptide innovative drug space.
Chen Lei, founder and chairman of Zhongsheng Quanpeptide, stated: "We are grateful for the trust and support of our existing and new shareholders. At this critical juncture of our Series C financing, we have both secured important BD transactions with multinational pharmaceutical companies and attracted backing from top-tier biopharma specialist investment institutions. This represents not only full recognition of our years of deep work in peptide innovative drugs, but also powerful momentum for our future growth. The company will continue to focus on frontier peptide innovative drug technologies, accelerate clinical and commercial progress for our core pipeline, and strive to bring more breakthrough treatment options to patients worldwide as soon as possible."
About Zhongsheng Quanpeptide
Hunan Zhongsheng Quanpeptide Biotech Co., Ltd. is a high-tech biopharmaceutical company dedicated to driving innovation in global peptide-based new drug R&D, committed to becoming a novel engine for innovative drug discovery and providing patients with more effective and safer therapeutic drugs. Founded in September 2017, the company is headquartered in Zhuzhou, Hunan, China.
The company owns proprietary peptide information compression technology (PICT) and has completed construction of an ultra-large peptide physical library containing nearly 500 million peptide sequences, along with six complementary molecular discovery libraries and twelve advantaged new drug development platforms. It possesses complete R&D capabilities spanning from target discovery to rapid advancement of preclinical candidate drugs. Focused on cutting-edge areas including PRC, PDC, and POC, the company has established over 50 innovative drug pipeline programs and reached multiple international collaborations with MNCs including Novartis and Eli Lilly.
